SAFI BIOTHERAPEUTICS INC

Biotech · Private

Designer red blood cells manufactured from induced pluripotent stem cells for use as diagnostic reagents in antibody identification

Grants
$568K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
4
0 granted · 4 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Manufacturing Process Intensification for Pluripotent Stem Cell-Derived Rare Red Cell Production$568,264
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2761KOLIBER BIOSCIENCES INC.——
2762VIRTUS THERAPEUTICS CORPORATION——
2763SPECIFICA, INC.——
2764SAFI BIOTHERAPEUTICS INC——
2765NANOVALENT PHARMACEUTICALS INC——
2766Florey Biosciences, Inc.—$1.4M
2767JSK THERAPEUTICS INC.—$963K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 4
  • Method For Culturing Cells Requiring A Supply Of Ironapplication
  • Method For Producing High-density Culture Cellsapplication
  • Method For Producing Culture Cells Requiring A Supply Of Ferric Ironapplication
  • Process For Producing Cultured Red Blood Cellsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.